These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2019 related articles for article (PubMed ID: 29807001)

  • 1. Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
    Lopes RD; Steffel J; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Hamilton M; Friend K; Gupta K; Mardekian J; Pan X; Baser O; Jones WS
    Am J Med; 2018 Sep; 131(9):1075-1085.e4. PubMed ID: 29807001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
    Lopes RD; Thomas L; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Friend K; Mardekian J; Pan X; Yuce H; Jones WS
    Am J Cardiol; 2021 Jun; 148():69-77. PubMed ID: 33667438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
    Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
    Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
    Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
    BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
    Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
    J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims.
    Lip GYH; Noxon V; Kang A; Luo X; Atreja N; Han S; Cheng D; Jiang J; Abramovitz L; Deitelzweig S
    J Thromb Thrombolysis; 2024 Aug; 57(6):1092-1102. PubMed ID: 38698197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
    Amin A; Keshishian A; Hines DM; Dina O; Le H; Rosenblatt L; Liu X; Zhang Q; Vo L
    Curr Med Res Opin; 2022 Dec; 38(12):2131-2140. PubMed ID: 35993487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
    Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E
    PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
    Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
    J Manag Care Spec Pharm; 2018 Sep; 24(9):911-920. PubMed ID: 30156450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation.
    Yang L; Brooks MM; Glynn NW; Zhang Y; Saba S; Hernandez I
    Am J Cardiol; 2020 Jul; 126():29-36. PubMed ID: 32359718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure.
    Amin A; Garcia Reeves AB; Li X; Dhamane A; Luo X; Di Fusco M; Nadkarni A; Friend K; Rosenblatt L; Mardekian J; Pan X; Yuce H; Keshishian A
    PLoS One; 2019; 14(3):e0213614. PubMed ID: 30908512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 101.